Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 59Squamous Cell Carcinoma of Head and Neck 38Nasopharyngeal Carcinoma 27Lung Neoplasms 26Biliary Tract Neoplasms 24Uterine Cervical Neoplasms 23Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 19Cholangiocarcinoma 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 14Ovarian Neoplasms 14Neoplasms 14Neoplasm Metastasis 13Esophageal Neoplasms 13Colorectal Neoplasms 12Carcinoma 12Stomach Neoplasms 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Carcinoma, Transitional Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Recurrence 6Pancreatic Neoplasms 6Nasopharyngeal Neoplasms 5Gallbladder Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5

Interventions

zaleplon 1olaparib 1Rehabilitation 1Psychotherapy 1Paclitaxel 1Oxaliplatin 1Olanzapine 1Nivolumab 1Niacin 1Injections 1Health Services Needs and Demand 1Gemcitabine 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Cancer × Cisplatin × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡